Retatrutide vs semaglutide: receptor pharmacology and trial results compared

The core difference: semaglutide activates only the GLP-1 receptor, while retatrutide activates the GIP, GLP-1 and glucagon receptors. Semaglutide is an approved medicine sold as Ozempic, Wegovy and Rybelsus. Retatrutide is investigational. In separate trials, retatrutide's phase 2 obesity study (Jastreboff et al., NEJM 2023) reported a mean 24.2% weight reduction at 48 weeks in its highest-dose arm, while semaglutide 2.4 mg in STEP 1 (Wilding et al., NEJM 2021) reported 14.9% at 68 weeks. Those numbers are not a head-to-head comparison: the trials differ in size, duration, population and phase, and no published trial has compared the two directly.

Retatrutide vs semaglutide at a glance

Receptor pharmacology: one receptor vs three

Semaglutide was engineered from human GLP-1 with two key changes described by Lau and colleagues (Journal of Medicinal Chemistry, 2015): an amino acid substitution that protects it from DPP-4 cleavage, and a C18 fatty diacid attached through a linker that binds serum albumin. Those changes took native GLP-1's minutes-long half-life to about a week. Everything semaglutide does runs through one receptor: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and appetite effects in the brain.

Retatrutide uses the same albumin-binding strategy but on a peptide designed to engage three receptors. Coskun et al. (Cell Metabolism, 2022) reported that it is more potent than native GIP at the GIP receptor and less potent than native GLP-1 and glucagon at theirs. The glucagon component is the real departure. Semaglutide suppresses glucagon secretion; retatrutide activates the glucagon receptor directly, which in preclinical work increased energy expenditure and hepatic fat oxidation. The apparent paradox is resolved by balance: incretin activity counters glucagon's effect on blood glucose, leaving its effects on liver and energy metabolism.

Tirzepatide sits between them with two receptors (GIP and GLP-1). That middle comparison is covered in retatrutide vs tirzepatide and tirzepatide vs semaglutide, and all three appear in the GLP-1 class comparison.

Retatrutide vs semaglutide weight loss: what separate trials reported

This is the comparison most people search for, so it needs the most careful framing. The figures below are the published primary results of different trials. They are placed side by side for orientation, not to rank the molecules.

Why the comparison is weaker than it looks:

• Different phases. Phase 2 trials are smaller and often show larger effects than the phase 3 trials that follow, partly because of population selection and tighter conditions.
• Different durations. 48 weeks vs 68 weeks, and retatrutide's higher-dose arms had not plateaued at 48 weeks.
• Different populations and eras. Baseline weight, sex ratio, comorbidities, and background care all differ.
• Different dropout handling. Treatment-regimen vs efficacy estimands can move mean results by several points.

A fair summary is that the retatrutide phase 2 effect sizes were larger than those reported for semaglutide, and that a direct randomised comparison or the full phase 3 data are needed to say by how much. In glycaemic control, the retatrutide type 2 diabetes trial (Rosenstock et al., Lancet 2023) did include an active GLP-1 comparator, dulaglutide 1.5 mg, and reported larger HbA1c reductions at the higher retatrutide doses.

Safety and tolerability compared

Both molecules share the incretin-class profile: gastrointestinal events (nausea, diarrhoea, vomiting, constipation) that are dose-related and concentrated during escalation, and increases in resting heart rate. Semaglutide's profile is characterised from large phase 3 programs and the SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023), which reported a 20% reduction in major adverse cardiovascular events versus placebo in people with established cardiovascular disease and overweight or obesity, without diabetes. Retatrutide's profile is so far characterised mainly from phase 1 and 2, where heart rate increases were dose-dependent and peaked around week 24. Whether the glucagon arm adds distinct long-term effects is an open question for phase 3. More detail is in retatrutide clinical trials explained.

Handling the reference standards in the lab

For bench work, the two behave similarly: both are lyophilized acylated peptides that reconstitute in bacteriostatic water and are stored at 2 to 8 C once in solution. Lumera Labs supplies semaglutide (20 mg) and retatrutide in 5 mg, 10 mg and 20 mg vials. The retatrutide 10 mg lot has a published HPLC-UV certificate at Lab Results; for semaglutide and the other retatrutide sizes a COA is available on request. Concentration math for each vial is in the peptide calculator, the reconstitution charts (for example semaglutide 20 mg and retatrutide 10 mg), and how to reconstitute retatrutide.

Which is the better research tool?

That depends on the question. Semaglutide is the cleaner tool for isolating GLP-1 receptor biology, and it has the deepest clinical literature to anchor findings against. Retatrutide is the tool when the question involves glucagon-receptor contributions, hepatic lipid handling, or how a third receptor changes an incretin response. Studies that include both, often with tirzepatide as a middle arm, can attribute effects to each receptor step by step.

Frequently asked questions